GLP-1 medications sit at the center of one of the most difficult benefit decisions employers face in 2026. These therapies are increasingly used to treat type 2 diabetes, obesity, and related cardiometabolic conditions. At the same time, they bring substantial pharmacy costs, tighter utilization controls, and growing frustration among employees who assume a prescription automatically means a drug will be covered.

For employers and health plan sponsors, the question is no longer whether GLP-1s matter. The challenge is how to provide access in a way that balances clinical value, affordability, fiduciary responsibilities, and participant expectations.

Many GLP-1 products carry list prices that range from several hundred dollars to more than $1,000 per month, depending on the medication and dosage. They are widely viewed as a significant driver of rising pharmacy costs. In response, employers, health plans, and pharmacy benefit managers are moving away from broad, open-ended coverage and toward more structured benefit designs. Access now depends not only on a clinician’s prescription, but also on whether a member meets the plan’s clinical and administrative requirements.

The following five issues now define the GLP-1 coverage discussion for employers and benefit decision-makers.

1. Coverage Is Narrowing to FDA-Approved Indications

The first issue is eligibility.

Most health plans are more willing to cover GLP-1 therapies for FDA-approved uses in type 2 diabetes and certain cardiometabolic conditions. Some also extend coverage to FDA-approved obesity and chronic weight-management indications. Far fewer plans are willing to cover off-label use tied to cosmetic or unsupervised weight loss.

That distinction matters because different GLP-1 medications are approved for different conditions. Some formulations are indicated for blood sugar management in type 2 diabetes, others for chronic weight management, and a growing number have received additional approvals related to cardiovascular risk reduction in certain high-risk populations. Coverage policies often track those labels closely. Diabetes and cardiovascular indications tend to receive priority, while obesity-related coverage remains more variable and often depends on plan design and cost considerations.

This is often where participant confusion begins. An employee may hear success stories online, obtain a prescription through a physician or telehealth provider, and still learn that coverage is unavailable. If the prescription falls outside the plan’s approved criteria, the member may be responsible for the full cost of treatment. That gap between consumer expectations and actual benefit design has become a growing source of complaints for employers.

For organizations, limiting coverage to clearly defined, on-label uses serves several purposes. It creates a financial control mechanism, supports consistent decision-making, and provides a defensible framework for administering a rapidly growing and expensive category of care. Many employers that have historically excluded weight-management drugs remain cautious and prefer to monitor pricing trends, outcomes data, and market competition before expanding coverage.

2. Prior Authorization Requirements Are Becoming More Rigorous

The second issue involves utilization management.

Even when a plan covers GLP-1 therapies, access is increasingly subject to detailed prior authorization requirements.

To qualify for coverage, plans commonly require:

·        A documented diagnosis, such as type 2 diabetes or obesity that meets specified thresholds.

·        Minimum body mass index requirements.

·        Evidence of qualifying comorbidities, such as cardiovascular disease or sleep apnea, when relevant to the approved indication.

·        Documentation showing that lower-cost therapies were attempted first when clinically appropriate.

·        Participation in a structured weight-management or lifestyle program offered or recognized by the plan.

For employees, this changes the experience from a traditional pharmacy benefit into a multistep process. A prescription is often only the starting point. Members may need physician documentation, laboratory results, prior treatment histories, and formal attestations before approval is granted. Delays are common when providers do not submit information in the format required by the pharmacy benefit manager. Some plans also require enrollment in coaching or weight-management programs as a condition of coverage.

For employers, stronger prior authorization standards serve two purposes. First, they help direct high-cost therapies to members who meet evidence-based clinical criteria. Second, they create a transparent and defensible record showing that the plan is applying consistent standards rather than making ad hoc exceptions. Many organizations view these controls as essential to maintaining affordability while preserving access in clinically appropriate cases.

3. Continued Coverage Increasingly Depends on Measurable Results

The third issue is reauthorization.

GLP-1 coverage is increasingly time-limited and contingent on documented outcomes. Initial approvals are often granted for a defined period, with continued coverage dependent on measurable clinical progress and ongoing engagement.

To maintain coverage, participants may need to demonstrate:

·        A specified percentage of weight loss or a defined reduction in A1c levels.

·        Consistent medication adherence.

·        Continued participation in lifestyle or weight-management programs.

·        Ongoing physician supervision.

·        The absence of new safety concerns or contraindications.

This can create challenges for participants. Some respond well and achieve measurable improvements within the required timeframes. Others encounter side effects, supply disruptions, cost-sharing burdens, or inconsistent follow-up care that make it difficult to satisfy reauthorization requirements. If coverage is discontinued, individuals may have to stop treatment or pay out of pocket.

For employers, outcome-based reauthorization reflects an effort to connect spending with value. The potential benefits of GLP-1 therapy often emerge over many years, while employee turnover may prevent plans from realizing all long-term savings. Linking continued coverage to measurable outcomes helps organizations avoid paying indefinitely for treatments that do not appear to be delivering sufficient benefit, while preserving access for participants who are responding well.

4. Plan Design Is Shifting More Cost to Members

The fourth issue is cost sharing.

Organizations that continue to cover GLP-1 therapies are increasingly relying on benefit-design strategies to manage spending, including:

·        Specialty drug tiers with higher copayments or coinsurance.

·        Separate or higher deductibles for specialty medications.

·        Annual or lifetime limits on certain obesity-related services, where permitted.

·        Designated specialty pharmacies or approved dispensing channels.

These decisions reflect a simple reality: coverage alone does not determine affordability.

A medication can be covered and still create significant out-of-pocket costs for employees. Given current pricing levels, even moderate coinsurance obligations can create meaningful financial burdens. Costs can be especially high during the early months of treatment, when deductibles have not yet been met.

Participants may view these arrangements as cost-driven access restrictions, particularly when comparing their experience with advertising, social media discussions, or stories from friends enrolled in different plans. Employers, however, often view tiering structures, channel management, and cost-sharing requirements as among the few practical tools available to balance access with budget constraints. Increasingly, these design features have become primary mechanisms for managing utilization without eliminating coverage altogether.

5. PBMs and Vendors Are Increasing Oversight of Prescribing Pathways

The fifth issue involves oversight.

Employers are relying more heavily on pharmacy benefit managers, specialty vendors, and care-management partners to monitor:

·        Telehealth and direct-to-consumer prescribing channels.

·        Use of compounded or otherwise unapproved GLP-1 products.

·        Adherence and persistence rates.

·        Alignment among prescriptions, clinical criteria, and formulary requirements.

Federal regulators have expressed concerns about unapproved or improperly compounded GLP-1 products marketed online for weight loss. As a result, many employer-sponsored plans exclude compounded versions except under limited circumstances. As supply constraints for branded medications have eased, some organizations have also become more comfortable scrutinizing telehealth-generated prescriptions that do not align with plan requirements or documentation standards.

For participants, this means that even a legitimate prescription may be delayed or denied if it originates from a source that does not satisfy plan requirements. Members may be asked to restart the process through an in-network provider, an approved telehealth partner, or a designated specialty pharmacy.

From the employer perspective, these controls are intended to reduce inappropriate utilization, improve documentation quality, and strengthen negotiating leverage with pharmacy benefit managers and manufacturers. However, they also increase communication risks if plan requirements are not clearly explained.

The Financial Reality Employers Cannot Ignore

All five issues share the same underlying challenge: a large potentially eligible population combined with high treatment costs.

A substantial share of U.S. adults could potentially qualify for GLP-1 therapy when type 2 diabetes, obesity, and related cardiometabolic conditions are considered together. When large populations become eligible for expensive therapies, even moderate utilization can materially affect plan-level pharmacy and medical spending.

For that reason, most employers are not treating GLP-1s as a routine formulary update. Instead, they are approaching them as a strategic category that requires active management across eligibility, authorization, reauthorization, adherence, and participant communication.

Industry surveys and employer-benefit research continue to point to rising health care costs in 2026 and beyond. GLP-1 therapies, along with other specialty medications, are consistently identified as significant contributors to that trend.

The market itself also continues to evolve. New products, formulations, and combination therapies remain in development. Competition may eventually influence pricing and contracting arrangements. Ongoing clinical research could also expand approved indications in areas such as cardiovascular disease, liver disease, and sleep apnea, potentially changing how employers evaluate the value of treatment.

Until the economics change materially, however, organizations will likely continue to emphasize tighter eligibility standards, outcome-based monitoring, and disciplined utilization management.

What Employers Should Watch Next

Three questions are likely to shape future GLP-1 coverage strategies.

First, how will FDA approvals and clinical evidence evolve? Expanded indications in high-cost and high-risk conditions may increase pressure to broaden coverage, even if employers remain cautious about cosmetic or off-label uses.

Second, can plans successfully connect coverage to measurable outcomes? Programs that combine GLP-1 therapy with lifestyle interventions, adherence support, and outcome-based monitoring will play an important role in determining whether employers view costs as justified.

Third, will market competition ease pricing pressures? New entrants, alternative formulations, and future generic or biosimilar competition could create opportunities to improve affordability and renegotiate contracting arrangements.

For employers evaluating long-term health care costs, the central challenge remains balancing access, clinical value, and affordability. Organizations that establish clear eligibility standards, outcome-based monitoring, and transparent participant communication will likely be better positioned to manage GLP-1 utilization effectively. While these therapies can provide meaningful clinical benefits, current pricing and utilization trends still require disciplined oversight and carefully defined coverage rules.

The PEAK FORMula™: Planning Beyond Today’s Headlines

At West Advisory Group, we’ve spent decades helping families navigate the countless ebbs and flows that come with retirement. Markets fluctuate, tax laws change, healthcare costs evolve, and new financial challenges, like the growing impact of GLP-1 medications on employer health plans, continue to emerge. While we can’t control every headline or every policy decision, we’ve learned that successful retirement planning isn’t about predicting the future. It’s about preparing for it.

That’s why we developed our proprietary PEAK FORMula™, a comprehensive retirement planning process designed specifically for individuals and families who are within five years of retirement and preparing to transition from the accumulation phase of life into the distribution phase. Rather than reacting to every change, our team of specialists focuses on the areas you can control, creating a flexible strategy that adapts as your retirement unfolds.

A Team Approach for Every Stage of Retirement

Questions surrounding employer healthcare costs, evolving benefit programs, and changing medical technologies reinforce an important reality: retirement planning is no longer just about investments. It requires thoughtful coordination across taxes, income planning, healthcare, estate planning, risk management, and long-term financial security.

At West Advisory Group, our team of experts works together to address each of these interconnected areas through the PEAK FORMula™, helping clients make informed decisions with confidence instead of emotion. We’ve seen market booms and recessions, legislative changes, healthcare reforms, and economic uncertainty. Those experiences have reinforced a simple truth: while we can’t control what happens around us, we can control how well we’re prepared for it.

If you’re within five years of retirement and wondering whether your current plan is built to handle life’s inevitable changes, we’d welcome the opportunity to show you how the PEAK FORMula™ can help you move into retirement with greater clarity, confidence, and peace of mind. After all, retirement isn’t about avoiding life’s twists and turns; it’s about having a plan that’s built to navigate them.